fibulin-5基因在人脑胶质瘤中的表达、作用及机制研究
|
摘要
背景:胶质瘤是中枢神经系统内最常见的恶性肿瘤,占颅内肿瘤的40%-50%。其呈侵袭性生长,总体疗效不佳,尤其是高分级胶质瘤,具有高度问变的生长特点,术后复发快、预后差,严重威胁人类健康,是神经外科治疗中相对棘手的难治性肿瘤之一。增殖的微血管对胶质瘤的恶性生物学行为起着重要作用。在胶质瘤的分级标准中,将血管的形态学改变作为恶性指标之一,明显不同于颅外其他肿瘤,无疑将血管生成在该瘤中的作用上升到一个新的高度。目前抗血管生成作为肿瘤治疗的新方法,已迅速发展为重要的抗癌策略,并成为肿瘤治疗领域的研究热点。在经手术切除、放疗和化疗等综合治疗仍无法从根本上改善胶质瘤预后的情况下,抗血管生成治疗有可能成为改善胶质瘤预后的突破口。
fibulin-5是细胞外基质蛋白家族fibulin家族中的成员,亦称为FBLN-5、DANCE或EVEC,在人染色体中位于14q32.1,其蛋白大小约60KDa。fibulin-5是一种含有448个氨基酸的糖蛋白,含有6个与钙离子结合的表皮生长因子样(EGF-like)区域,其中一个区域含有能与整合素结合的RGD基序(integrin-binding RGD motif)。后者能介导内皮细胞粘附,能与细胞表面的整合素αvβ3、αvβ5和α9β1结合。
fibulin-5广泛分布于富含弹性蛋白的组织中,能直接与弹性蛋白原(tropoelastin)结合,或者连接微原纤维(microfibril),在形成弹性纤维过程中具有重要作用,而且可以影响血管的发育和修复。此外,fibulin-5还能通过促进组织肉芽增生和Ⅰ型胶原表达来促进伤口愈合;这与细胞的增殖、运动和侵袭有关。因此既往对其研究主要集中在弹性蛋白病变方面,对其缺失或基因突变而导致的多种皮肤、血管和肺组织疾病已经有了充分的共识,认为它是治疗血管硬化、肺气肿和皮肤松弛症等疾病的重要靶点。
有研究指出fibulin-5可以促进人HT1080纤维肉瘤细胞的DNA合成,并增强其侵袭基底膜的能力;但是在肾癌、乳腺癌、卵巢癌和结肠癌等恶性肿瘤中,fibulin-5的表达明显降低。另有实验发现fibulin-5能通过抑制肿瘤血管生成来减缓老鼠癌性肿瘤的生长。这些研究显示fibulin-5的表达与肿瘤发生、发展和血管生成存在紧密联系。但是目前fibulin-5对肿瘤细胞的生物学特性的影响还不甚清楚;在肿瘤血管生成中的具体调控机制还有待进一步研究;在胶质瘤中的表达及作用在国内外亦未见到相关报道。HUVEC-2C是经典的血管内皮细胞模型,U251是来源于多形性胶质母细胞瘤WHOⅣ级的细胞株。因此在本文中,我们拟首先探讨fibulin-5在人脑胶质瘤中的表达情况。然后拟通过体外单纯血管内皮细胞模型(HUVEC-2C)以及Transwell培养技术构建的HUVEC-2C和U251共培养的胶质瘤微环境模型探讨fibulin-5与胶质瘤发生、发展的关系。
第一章fibulin-5在人脑胶质瘤组织中的表达及意义
目的:初步探讨fibulin-5在胶质瘤中的表达情况及其与胶质瘤发生、发展的关系。方法:通过免疫组织化学方法检测fibulin-5蛋白、Ki-67,FactorⅧ及HIF-1α蛋白在正常脑组织和胶质瘤组织中的表达情况,并分析fibulin-5蛋白的表达与胶质瘤的病理分级、胶质瘤Ki-67标记指数(Ki-67 LI)、微血管密度(MVD)及HIF-1α蛋白表达的关系。实验分三组:对照组为正常脑组织(7例)、低分级胶质瘤组(21例WHO分类Ⅰ～Ⅲ级的胶质瘤石蜡标本)和高分级胶质瘤组(19例WHO分类Ⅲ～Ⅳ级的胶质瘤石蜡标本)。通过RT-PCR检测fibulin-5 mRNA在正常脑组织和胶质瘤组织中的表达情况。实验分三组:对照组为正常脑组织(7例)、低分级胶质瘤组(22例WHO分类Ⅰ～Ⅱ级的新鲜胶质瘤标本)和高分级胶质瘤组(15例WHO分类Ⅲ～Ⅳ级的新鲜胶质瘤标本)。结果:fibulin-5蛋白主要分布于细胞之间,偶可在实质细胞及血管内皮细胞胞浆中发现表达。均表现为黄色或棕黄色着色。fibulin-5蛋白在对照组正常脑组织中,所有7例标本均检测到表达;在低分级胶质瘤组中,21例标本有13例检测到表达;在高分级胶质瘤组中,19例标本有4例检测到表达。正常脑组织标本的fibulin-5蛋白表达阳性率以及平均IRS值和低分级胶质瘤组相比无统计学差异(P＞0.05);高分级胶质瘤组的fibulin-5蛋白表达阳性率以及平均IRS值均低于正常脑组织和低分级胶质瘤组的表达,统计学检测有差异(P＜0.05)。在有经验的病理科医师指导下,观察实验各组的阳性标本,可以发现fibulin-5蛋白在组织血管中表达的位置是不一样的,在正常脑组织中主要表达于管径较大的血管;在低分级胶质瘤中主要表达于管径微小的血管;在高分级胶质瘤中未发现在组织血管表达。fibulin-5 mRNA在对照组正常脑组织中,所有7例标本均检测到表达;在低分级胶质瘤组中,22例标本有14例检测到表达;在高分级胶质瘤组中,15例标本有3例检测到表达。正常脑组织标本的fibulin-5 mRNA表达阳性率以及平均IOD值和低分级胶质瘤组相比无统计学差异(P＞0.05);高分级胶质瘤组的fibulin-5 mRNA表达阳性率以及平均IOD值均低于正常脑组织和低分级胶质瘤组的表达,统计学检测有差异(P＜0.05)。在胶质瘤组织中,fibulin-5蛋白和mRNA在不同性别及年龄的表达无统计学差异(P＞0.05)。同时直线相关分析发现,fibulin-5蛋白在胶质瘤中的表达与胶质瘤的病理分级、MVD、HIF-1α及Ki-67均存在负相关(r=-0.455,-0.779,-0.320;P=0.003,0.000,0.044)。结论:fibulin-5在正常脑组织中表达,其在胶质瘤组织中表达的变化可能与胶质瘤的进展和血管生成存在联系。
第二章构建人fibulin-5基因表达的慢病毒质粒并感染HUVEC—2C筛选混合稳定株
目的:构建人fibulin-5基因表达的慢病毒质粒并感染HUVEC—2C筛选混合稳定株,为体外研究fibulin-5的生物学功能提供材料。方法:通过RT-PCR检测fibulin-5 mRNA在HUVEC-2C和U251细胞株的表达。通过构建含有fibulin-5的重组pGC-FU载体,并用293T细胞包装病毒,将得到的人fibulin-5基因表达的慢病毒质粒感染HUVEC-2C并筛选,最终得到人fibulin-5基因表达的HUVEC-2C混合稳定株。结果:fibulin-5 mRNA在HUVEC-2C和U251细胞株均不表达。在人fibulin-5基因表达的HUVEC-2C混合稳定株中,通过Western blot和Real-time PCR方法检测到fibulin-5的表达。结论:成功建立了人fibulin-5基因表达的HUVEC-2C混合稳定株,为进一步实验做准备。
第三章人fibulin-5基因表达对内皮细胞生物学特性的影响
目的:探讨人fibulin-5基因表达对内皮细胞生物学特性的影响,以明确其在血管生成中的作用及机制。方法:实验分3组:CON组(未作任何干扰的HUVEC-2C细胞株);NC组(阴性对照慢病毒感染HUVEC-2C筛选的混合稳定细胞株);KD组(人fibulin-5基因表达的慢病毒质粒感染HUVEC-2C筛选的混合稳定细胞株)。通过MTT法、结晶紫染色法、流式细胞仪分析法和成管能力实验检测人fibulin-5基因表达对HUVEC-2C的增殖、粘附、迁移、凋亡和成管能力的影响。结果:MTT检测发现在相同的时问点,KD组的OD值明显低于CON组和NC组(P＜0.05);检测粘附能力试验中,接种30min后KD组结晶紫OD值明显高于CON组和NC组(P＜0.05);检测迁移能力实验中,KD组结晶紫OD值明显低于CON组和NC组(P＜0.05);培养至第3天进行流式细胞仪检测可见,KD组HUVEC细胞G0/G1期分布明显多于NC组和CON组(P＜0.05);S期分布明显少于NC组和CON组(P＜0.05):G_2/M期分布和细胞凋亡率三组无明显差别(P＞0.05)。检测成管能力实验中,CON组、NC组及KD组管状结构相对面积并无明显差异(P=0.305),但是KD组HUVEC-2C成管数明显低于CON组和NC组(P<0.05)。在检测增殖、粘附、迁移、凋亡及成管能力实验中,CON组和NC组无明显差异(P>0.05)。结论:人fibulin-5基因表达后,可以使内皮细胞的细胞周期迟滞;抑制内皮细胞的增殖、迁移和成管能力;可以增强内皮细胞的粘附能力。其可能通过减少血管基底膜的溶解、维持细胞外基质的稳定性、增强内皮细胞的粘附能力来抑制血管新生和维护原有血管的稳定。
第四章人fibulin-5基因表达对胶质瘤-内皮细胞微生态系统中内皮细胞和肿瘤细胞生物学特性的影响
目的:探讨人fibulin-5基因在胶质瘤微环境中表达对内皮细胞和肿瘤细胞生物学特性的影响,以明确其在胶质瘤发生、发展中的作用。方法:用Transwell技术体外建立了U251细胞与HUVEC共培养模型。实验分3组:CON组(其中HUVEC-2C未加任何干扰因素);NC组(其中HUVEC-2C是阴性对照慢病毒感染HUVEC-2C筛选的混合稳定细胞株);KD组(其中HUVEC-2C是人fibulin-5基因表达的慢病毒质粒感染HUVEC-2C筛选的混合稳定细胞株)。通过MTT法、结晶紫染色法和成管能力实验检测人fibulin-5基因在胶质瘤微环境中表达对HUVEC-2C的增殖、粘附、迁移和成管能力的影响。通过MTT法和结晶紫染色法检测人fibulin-5基因在胶质瘤微环境中表达对U251的增殖和迁移能力的影响。结果:①在检测人fibulin-5基因在胶质瘤微环境中表达对HUVEC-2C生物学功能影响的实验中发现:MTT法结果示在相同的时间点,KD组的OD值明显低于CON组和NC组(P＜0.05);检测粘附能力试验中,接种30min后KD组结晶紫OD值明显高于CON组和NC组(P＜0.05);检测迁移能力实验中,KD组结晶紫OD值明显低于CON组和NC组(P＜0.01);检测成管能力实验中,CON组,NC组及KD组管状结构相对面积并无明显差异(P=0.996),但是KD组HUVEC-2C成管数明显低于CON组和NC组(P＜0.05),KD组的管型结构更加规则。在检测增殖、粘附、迁移及成管能力实验中,CON组和NC组无明显差异(P＞0.05)。②在检测人fibulin-5基因在胶质瘤微环境中表达对U251生物学功能影响的实验中发现:MTT法结果示从培养48小时后开始,在相同的时间点,KD组的OD值明显低于CON组和NC组(P＜0.05),CON组和NC组的OD值无明显差异(P＞0.05);检测迁移能力实验中,CON组、NC组和KD组结晶紫OD值比较无明显差异(P=0.819)结论:人fibulin-5基因在胶质瘤微环境中表达可抑制内皮细胞的增殖、迁移和成管能力;可以增强内皮细胞的粘附能力。其可抑制血管新生和维护原有血管的稳定,并有可能使“肿瘤血管相对正常化”;此外,它还可以抑制U251的增殖,从而抑制肿瘤的增殖和转移。
BACKGROUND:Gliomas,especially the high-grade gliomas,are the most common primary brain malignant tumor whose characteristic is quickly recurrence and an extremely poor prognosis,despite advances in surgical and clinical neuro-oncology.The microvessel density is an independent index in judging the grade of gliomas as to the conclusive evidence.Angiogenesis maybe the most important factor for the proliferation and metastasis of gliomas,and the anti-angiogenesis treatment maybe the most worth expectation for the better prognosis of the patients who had got the gliomas.
fibulin-5(FBLN-5,DANCE or EVEC),which is a 448 amino acid glycoprotein,is the member of the fibulin family of extracellular matrix (ECM) proteins,and is mapped in chromosome 14q32.1.It contains six EGF-like repeats,all containing consensus sequences for Ca~(2+)-binding(CB)-EGF-like repeats.The first CB-EGF-like repeat of fibulin-5 also contains a RGD sequence,which mediates interaction with cell surface integrins,includingαvβ3、αvβ5 andα9β1.
fibulin-5 is a multifunctional extracellular matrix protein that mediates cell-cell and cell-matrix communication.It regulates the formation and assembly of elastic fibers primarily by binding tropoelastin, and secondarily by binding lysyl oxidase-like 1(Loxl-1) and EMILIN-1 (elastin microfibril interface-located protein).It can enhanced wound closure and healing by increasing tissue granulation and type I collagen expression.Its expression is normally low in adult vasculature,but it is remarkably elevated in developing or injured blood vessels,and in uterine myometrial arteries undergoing cyclic angiogenesis.Also,it takes an important role in the angiosclerosis and cutis laxa.
The expression of fibulin-5 also augments the tumorigenicity of human HT1080 fibrosarcoma cells by increasing their DNA synthesis, migration toward fibronectin,and invasion through synthetic basement membranes.In stark contrast,Its expression is down-regulated in the majority of metastatic human malignancies,particularly in cancers of the kidney,breast,ovary,and colon.It also can slow the growth of cancer tumors in mice by preventing blood vessels from sprouting,fibulin-5 may play an important part in the tumor procession.In our research,we will discuss the role that fibulin-5 plays in the process of gliomas.
Part 1 Expression and function of fibulin-5 gene in the gliomas
Objective:The present study was carried out to investigate the expression of fibulin-5 in human glioma tissues.Methods:40 cases of formalin-fixed,paraffin-embedded specimens of tissue,including low-grade glioma of 21 patients(gradeⅠ～Ⅱ) and high-grade glioma of 19 patients(gradeⅢ～Ⅳ),and another normal brain tissues of 7 patients, were used to assess the expression status of fibulin-5 protein,Ki-67, FactorⅧand HIF-1αby immunohistochemical staining.The Ki-67 labeling index(LI) and microvessel density(MVD) were calculated. Then we also analyzed the correlation between fibulin-5's expression and the Ki-67 LI,MVD or the expression of HIF-1α.Another 44 cases of the fresh tissue,including low-grade glioma of 22 patients(gradeⅠ～Ⅱ), high-grade glioma of 15 patients(gradeⅢ～Ⅳ) and the normal brain tissues of 7 patients,were used to assess the expression status of fibulin-5 mRNA by RT-PCR.Results:The expression of the fibulin-5's protein usually lay between cell and cell or cell and matrix.In the normal brain tissue,it always could be found;in the low grade gliomas tissue,there were 13 sample could be found;in the high grade gliomas,there were only 4 sample could be found.The expression of the fibulin-5's protein in the normal brain tissues and the low grade gliomas were higher than its expression in the high grade gliomas(P＞0.05).The expression of fibulin-5's protein in the vessel which was in the normal brain tissue usually lay in the great vessel,but in the low grade tissue,it usually lay in the capillary vessel.The expression of the fibulin-5's protein inverse correlated with the degree of malignancy,Ki-67 LI,MVD and the expression of HIF-1αof human gliomas(r=-0.455,-0.779,-0.320;P =0.003,0.000,0.044 ).Then we found that fibulin-5's mRNA always expressed in the normal brain tissue;there were 14 sample could be found in the low grade gliomas tissue;there were only 3 sample could be found in the high grade gliomas tissue.The expression of the fibulin-5's mRNA in the normal brain tissues and the low grade gliomas were higher than its expression in the high grade gliomas(P＞0.05).Conclusion:fibulin-5 could expressed in the normal brain tissue.The expression of fibulin-5 may correlated with the process and the angiogenesis of gliomas.
Part 2 To construct the cell strain(HUVEC-2C) for expressing the fibulin-5 gene through the stable transfection
Objective:To construct an lentiviral vector carrying fibulin-5 gene and then stable transfected to the huaman umbilical vein endothelial cells -2C(HUVEC-2C).Methods:The expression of fibulin-5 in the HUVEC-2C and the U251 was checked by RT-PCR first.Then fibulin-5 was amplified by PCR and subcloned fibulin-5 into the lentiviral vector(pGC-FU),to generate the lentiviral expression vector, (pGC-FU-FIBULIN-5).Recombinant lentiviruses were produced by 293T cells following the co-transfection of pGC-FU-FIBULIN-5,with the packaging plasmids pHelper1.0 and pHelp2.0.So,we got the lentiveruses called KL425-LV.Last,we use the KL425-LV to stable transfect into HUVEC-2C and got the cell strain called Fibulin-5-GFP-LV. Results:There was no expression in the HUVEC-2C and the U251.The cell strain(Fibulin-5-GFP-LV) was expressing the fibulin-5 gene through the check by Western blot and Real-time PCR.Conclusion:The cell strain which was expressing the fibulin-5 gene was successed constructing.
Part 3 Effect on the bionomics of HUVEC-2C by the fibulin-5 gene expressing
Objective:The present study was carried out to investigate the effect on the bionomics of HUVEC-2C by the fibulin-5 gene expressing. Then we could figure out the function of the fibulin-5 during the angiogenesis.Methods:There were three groups in the experiment:CON group(used the normal HUVEC-2C),NC group(used the HUVEC-2C which was transfected the negative vector) and KD group(used the cell strain called Fibulin-5-GFP-LV,which was contructed in the Part 2).So we could exam the change of the ability of the proliferation,adhesion, invasion,apoptosis and vessel-sprouting of the HUVEC-2C during the fibulin-5 gene expressing.Results:By the MTT test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05).In the adhesion's test,the OD value in the KD group was higher than that in the CON group and the NC group(P＜0.05).In the invasion's test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05).By the flow cytometry's test,we found that the cell cycle in the KD group was prolonged(P＜0.05).In the vessel-sprouting abiltity test,we found that the number of the vessel was decreased in the KD group(P＜0.05). Conclusion:The expression of fibulin-5 gene could prolong the period of the cell cycle,inhibit the ability of the proliferation,invasion and the vessel-sprouting of HUVEC-2C.But it could enhance the ability of the adhesion,fibulin-5 gene expressing could inhibit the angiogenesis and make the vessel more stable.
Part 4 Effect on the bionomics of HUVEC-2C and U251 by fibulin-5 gene expressing in the gliomas's microenvironment
Objective:The present study was carried out to investigate the effect on the bionomics of HUVEC-2C or U251 by the fibulin-5 gene expressing in the gliomas's microenvironment.Then we could figure out the function of the fibulin-5 during the process of gliomas.Methods:We first constructed the gliomas's microenvironment by HUVEC-2C and U251 co-cultured.There were three groups in the experiment:CON group(used the normal HUVEC-2C),NC group(used the HUVEC-2C which was transfected the negative vector) and KD group(used the cell strain called Fibulin-5-GFP-LV,which was contructed in the Part 2).So we could exam the change of the ability of the proliferation,adhesion, invasion and vessel-sprouting of the HUVEC-2C during the fibulin-5 gene expressing in the gliomas's microenvironment.We also examed the change of ability of the proliferation and invasion of the U251 by the same way.Results:①Testing the change of the ability of HUVEC-2C's bionomics in the gliomas's microenvironment:By the MTT test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05).In the adhesion's test,the OD value in the KD group was higher than that in the CON group and the NC group (P＜0.05).In the invasion's test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05). In the vessel-sprouting ability test,we found that the number of the vessel was decreased in the KD group(P＜0.05).②Testing the change of the ability of U251's bionomics in the gliomas's microenvironment:By the MTT test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05).In the invasion's test, we found that there were no difference in the KD group,CON group and NC group(P＞0.05).Conclusion:The expression of fibulin-5 gene in the gliomas's microenvironment could inhibit the ability of the proliferation, invasion and the vessel-sprouting of HUVEC-2C.It could enhanced the ability of the adhesion of HUVEC-2C.It could also inhibit the U251 's reproductive activity,fibulin-5 gene expressing could inhibit the angiogenesis and make the vessel more stable in the gliomas's microenvironment.It mightbe make the tumor vessel normalization. Mightbe,it inhibit the gliomas's ability of the proliferation and the invasion directly.
fibulin-5是细胞外基质蛋白家族fibulin家族中的成员,亦称为FBLN-5、DANCE或EVEC,在人染色体中位于14q32.1,其蛋白大小约60KDa。fibulin-5是一种含有448个氨基酸的糖蛋白,含有6个与钙离子结合的表皮生长因子样(EGF-like)区域,其中一个区域含有能与整合素结合的RGD基序(integrin-binding RGD motif)。后者能介导内皮细胞粘附,能与细胞表面的整合素αvβ3、αvβ5和α9β1结合。
fibulin-5广泛分布于富含弹性蛋白的组织中,能直接与弹性蛋白原(tropoelastin)结合,或者连接微原纤维(microfibril),在形成弹性纤维过程中具有重要作用,而且可以影响血管的发育和修复。此外,fibulin-5还能通过促进组织肉芽增生和Ⅰ型胶原表达来促进伤口愈合;这与细胞的增殖、运动和侵袭有关。因此既往对其研究主要集中在弹性蛋白病变方面,对其缺失或基因突变而导致的多种皮肤、血管和肺组织疾病已经有了充分的共识,认为它是治疗血管硬化、肺气肿和皮肤松弛症等疾病的重要靶点。
有研究指出fibulin-5可以促进人HT1080纤维肉瘤细胞的DNA合成,并增强其侵袭基底膜的能力;但是在肾癌、乳腺癌、卵巢癌和结肠癌等恶性肿瘤中,fibulin-5的表达明显降低。另有实验发现fibulin-5能通过抑制肿瘤血管生成来减缓老鼠癌性肿瘤的生长。这些研究显示fibulin-5的表达与肿瘤发生、发展和血管生成存在紧密联系。但是目前fibulin-5对肿瘤细胞的生物学特性的影响还不甚清楚;在肿瘤血管生成中的具体调控机制还有待进一步研究;在胶质瘤中的表达及作用在国内外亦未见到相关报道。HUVEC-2C是经典的血管内皮细胞模型,U251是来源于多形性胶质母细胞瘤WHOⅣ级的细胞株。因此在本文中,我们拟首先探讨fibulin-5在人脑胶质瘤中的表达情况。然后拟通过体外单纯血管内皮细胞模型(HUVEC-2C)以及Transwell培养技术构建的HUVEC-2C和U251共培养的胶质瘤微环境模型探讨fibulin-5与胶质瘤发生、发展的关系。
第一章fibulin-5在人脑胶质瘤组织中的表达及意义
目的:初步探讨fibulin-5在胶质瘤中的表达情况及其与胶质瘤发生、发展的关系。方法:通过免疫组织化学方法检测fibulin-5蛋白、Ki-67,FactorⅧ及HIF-1α蛋白在正常脑组织和胶质瘤组织中的表达情况,并分析fibulin-5蛋白的表达与胶质瘤的病理分级、胶质瘤Ki-67标记指数(Ki-67 LI)、微血管密度(MVD)及HIF-1α蛋白表达的关系。实验分三组:对照组为正常脑组织(7例)、低分级胶质瘤组(21例WHO分类Ⅰ～Ⅲ级的胶质瘤石蜡标本)和高分级胶质瘤组(19例WHO分类Ⅲ～Ⅳ级的胶质瘤石蜡标本)。通过RT-PCR检测fibulin-5 mRNA在正常脑组织和胶质瘤组织中的表达情况。实验分三组:对照组为正常脑组织(7例)、低分级胶质瘤组(22例WHO分类Ⅰ～Ⅱ级的新鲜胶质瘤标本)和高分级胶质瘤组(15例WHO分类Ⅲ～Ⅳ级的新鲜胶质瘤标本)。结果:fibulin-5蛋白主要分布于细胞之间,偶可在实质细胞及血管内皮细胞胞浆中发现表达。均表现为黄色或棕黄色着色。fibulin-5蛋白在对照组正常脑组织中,所有7例标本均检测到表达;在低分级胶质瘤组中,21例标本有13例检测到表达;在高分级胶质瘤组中,19例标本有4例检测到表达。正常脑组织标本的fibulin-5蛋白表达阳性率以及平均IRS值和低分级胶质瘤组相比无统计学差异(P＞0.05);高分级胶质瘤组的fibulin-5蛋白表达阳性率以及平均IRS值均低于正常脑组织和低分级胶质瘤组的表达,统计学检测有差异(P＜0.05)。在有经验的病理科医师指导下,观察实验各组的阳性标本,可以发现fibulin-5蛋白在组织血管中表达的位置是不一样的,在正常脑组织中主要表达于管径较大的血管;在低分级胶质瘤中主要表达于管径微小的血管;在高分级胶质瘤中未发现在组织血管表达。fibulin-5 mRNA在对照组正常脑组织中,所有7例标本均检测到表达;在低分级胶质瘤组中,22例标本有14例检测到表达;在高分级胶质瘤组中,15例标本有3例检测到表达。正常脑组织标本的fibulin-5 mRNA表达阳性率以及平均IOD值和低分级胶质瘤组相比无统计学差异(P＞0.05);高分级胶质瘤组的fibulin-5 mRNA表达阳性率以及平均IOD值均低于正常脑组织和低分级胶质瘤组的表达,统计学检测有差异(P＜0.05)。在胶质瘤组织中,fibulin-5蛋白和mRNA在不同性别及年龄的表达无统计学差异(P＞0.05)。同时直线相关分析发现,fibulin-5蛋白在胶质瘤中的表达与胶质瘤的病理分级、MVD、HIF-1α及Ki-67均存在负相关(r=-0.455,-0.779,-0.320;P=0.003,0.000,0.044)。结论:fibulin-5在正常脑组织中表达,其在胶质瘤组织中表达的变化可能与胶质瘤的进展和血管生成存在联系。
第二章构建人fibulin-5基因表达的慢病毒质粒并感染HUVEC—2C筛选混合稳定株
目的:构建人fibulin-5基因表达的慢病毒质粒并感染HUVEC—2C筛选混合稳定株,为体外研究fibulin-5的生物学功能提供材料。方法:通过RT-PCR检测fibulin-5 mRNA在HUVEC-2C和U251细胞株的表达。通过构建含有fibulin-5的重组pGC-FU载体,并用293T细胞包装病毒,将得到的人fibulin-5基因表达的慢病毒质粒感染HUVEC-2C并筛选,最终得到人fibulin-5基因表达的HUVEC-2C混合稳定株。结果:fibulin-5 mRNA在HUVEC-2C和U251细胞株均不表达。在人fibulin-5基因表达的HUVEC-2C混合稳定株中,通过Western blot和Real-time PCR方法检测到fibulin-5的表达。结论:成功建立了人fibulin-5基因表达的HUVEC-2C混合稳定株,为进一步实验做准备。
第三章人fibulin-5基因表达对内皮细胞生物学特性的影响
目的:探讨人fibulin-5基因表达对内皮细胞生物学特性的影响,以明确其在血管生成中的作用及机制。方法:实验分3组:CON组(未作任何干扰的HUVEC-2C细胞株);NC组(阴性对照慢病毒感染HUVEC-2C筛选的混合稳定细胞株);KD组(人fibulin-5基因表达的慢病毒质粒感染HUVEC-2C筛选的混合稳定细胞株)。通过MTT法、结晶紫染色法、流式细胞仪分析法和成管能力实验检测人fibulin-5基因表达对HUVEC-2C的增殖、粘附、迁移、凋亡和成管能力的影响。结果:MTT检测发现在相同的时问点,KD组的OD值明显低于CON组和NC组(P＜0.05);检测粘附能力试验中,接种30min后KD组结晶紫OD值明显高于CON组和NC组(P＜0.05);检测迁移能力实验中,KD组结晶紫OD值明显低于CON组和NC组(P＜0.05);培养至第3天进行流式细胞仪检测可见,KD组HUVEC细胞G0/G1期分布明显多于NC组和CON组(P＜0.05);S期分布明显少于NC组和CON组(P＜0.05):G_2/M期分布和细胞凋亡率三组无明显差别(P＞0.05)。检测成管能力实验中,CON组、NC组及KD组管状结构相对面积并无明显差异(P=0.305),但是KD组HUVEC-2C成管数明显低于CON组和NC组(P<0.05)。在检测增殖、粘附、迁移、凋亡及成管能力实验中,CON组和NC组无明显差异(P>0.05)。结论:人fibulin-5基因表达后,可以使内皮细胞的细胞周期迟滞;抑制内皮细胞的增殖、迁移和成管能力;可以增强内皮细胞的粘附能力。其可能通过减少血管基底膜的溶解、维持细胞外基质的稳定性、增强内皮细胞的粘附能力来抑制血管新生和维护原有血管的稳定。
第四章人fibulin-5基因表达对胶质瘤-内皮细胞微生态系统中内皮细胞和肿瘤细胞生物学特性的影响
目的:探讨人fibulin-5基因在胶质瘤微环境中表达对内皮细胞和肿瘤细胞生物学特性的影响,以明确其在胶质瘤发生、发展中的作用。方法:用Transwell技术体外建立了U251细胞与HUVEC共培养模型。实验分3组:CON组(其中HUVEC-2C未加任何干扰因素);NC组(其中HUVEC-2C是阴性对照慢病毒感染HUVEC-2C筛选的混合稳定细胞株);KD组(其中HUVEC-2C是人fibulin-5基因表达的慢病毒质粒感染HUVEC-2C筛选的混合稳定细胞株)。通过MTT法、结晶紫染色法和成管能力实验检测人fibulin-5基因在胶质瘤微环境中表达对HUVEC-2C的增殖、粘附、迁移和成管能力的影响。通过MTT法和结晶紫染色法检测人fibulin-5基因在胶质瘤微环境中表达对U251的增殖和迁移能力的影响。结果:①在检测人fibulin-5基因在胶质瘤微环境中表达对HUVEC-2C生物学功能影响的实验中发现:MTT法结果示在相同的时间点,KD组的OD值明显低于CON组和NC组(P＜0.05);检测粘附能力试验中,接种30min后KD组结晶紫OD值明显高于CON组和NC组(P＜0.05);检测迁移能力实验中,KD组结晶紫OD值明显低于CON组和NC组(P＜0.01);检测成管能力实验中,CON组,NC组及KD组管状结构相对面积并无明显差异(P=0.996),但是KD组HUVEC-2C成管数明显低于CON组和NC组(P＜0.05),KD组的管型结构更加规则。在检测增殖、粘附、迁移及成管能力实验中,CON组和NC组无明显差异(P＞0.05)。②在检测人fibulin-5基因在胶质瘤微环境中表达对U251生物学功能影响的实验中发现:MTT法结果示从培养48小时后开始,在相同的时间点,KD组的OD值明显低于CON组和NC组(P＜0.05),CON组和NC组的OD值无明显差异(P＞0.05);检测迁移能力实验中,CON组、NC组和KD组结晶紫OD值比较无明显差异(P=0.819)结论:人fibulin-5基因在胶质瘤微环境中表达可抑制内皮细胞的增殖、迁移和成管能力;可以增强内皮细胞的粘附能力。其可抑制血管新生和维护原有血管的稳定,并有可能使“肿瘤血管相对正常化”;此外,它还可以抑制U251的增殖,从而抑制肿瘤的增殖和转移。
BACKGROUND:Gliomas,especially the high-grade gliomas,are the most common primary brain malignant tumor whose characteristic is quickly recurrence and an extremely poor prognosis,despite advances in surgical and clinical neuro-oncology.The microvessel density is an independent index in judging the grade of gliomas as to the conclusive evidence.Angiogenesis maybe the most important factor for the proliferation and metastasis of gliomas,and the anti-angiogenesis treatment maybe the most worth expectation for the better prognosis of the patients who had got the gliomas.
fibulin-5(FBLN-5,DANCE or EVEC),which is a 448 amino acid glycoprotein,is the member of the fibulin family of extracellular matrix (ECM) proteins,and is mapped in chromosome 14q32.1.It contains six EGF-like repeats,all containing consensus sequences for Ca~(2+)-binding(CB)-EGF-like repeats.The first CB-EGF-like repeat of fibulin-5 also contains a RGD sequence,which mediates interaction with cell surface integrins,includingαvβ3、αvβ5 andα9β1.
fibulin-5 is a multifunctional extracellular matrix protein that mediates cell-cell and cell-matrix communication.It regulates the formation and assembly of elastic fibers primarily by binding tropoelastin, and secondarily by binding lysyl oxidase-like 1(Loxl-1) and EMILIN-1 (elastin microfibril interface-located protein).It can enhanced wound closure and healing by increasing tissue granulation and type I collagen expression.Its expression is normally low in adult vasculature,but it is remarkably elevated in developing or injured blood vessels,and in uterine myometrial arteries undergoing cyclic angiogenesis.Also,it takes an important role in the angiosclerosis and cutis laxa.
The expression of fibulin-5 also augments the tumorigenicity of human HT1080 fibrosarcoma cells by increasing their DNA synthesis, migration toward fibronectin,and invasion through synthetic basement membranes.In stark contrast,Its expression is down-regulated in the majority of metastatic human malignancies,particularly in cancers of the kidney,breast,ovary,and colon.It also can slow the growth of cancer tumors in mice by preventing blood vessels from sprouting,fibulin-5 may play an important part in the tumor procession.In our research,we will discuss the role that fibulin-5 plays in the process of gliomas.
Part 1 Expression and function of fibulin-5 gene in the gliomas
Objective:The present study was carried out to investigate the expression of fibulin-5 in human glioma tissues.Methods:40 cases of formalin-fixed,paraffin-embedded specimens of tissue,including low-grade glioma of 21 patients(gradeⅠ～Ⅱ) and high-grade glioma of 19 patients(gradeⅢ～Ⅳ),and another normal brain tissues of 7 patients, were used to assess the expression status of fibulin-5 protein,Ki-67, FactorⅧand HIF-1αby immunohistochemical staining.The Ki-67 labeling index(LI) and microvessel density(MVD) were calculated. Then we also analyzed the correlation between fibulin-5's expression and the Ki-67 LI,MVD or the expression of HIF-1α.Another 44 cases of the fresh tissue,including low-grade glioma of 22 patients(gradeⅠ～Ⅱ), high-grade glioma of 15 patients(gradeⅢ～Ⅳ) and the normal brain tissues of 7 patients,were used to assess the expression status of fibulin-5 mRNA by RT-PCR.Results:The expression of the fibulin-5's protein usually lay between cell and cell or cell and matrix.In the normal brain tissue,it always could be found;in the low grade gliomas tissue,there were 13 sample could be found;in the high grade gliomas,there were only 4 sample could be found.The expression of the fibulin-5's protein in the normal brain tissues and the low grade gliomas were higher than its expression in the high grade gliomas(P＞0.05).The expression of fibulin-5's protein in the vessel which was in the normal brain tissue usually lay in the great vessel,but in the low grade tissue,it usually lay in the capillary vessel.The expression of the fibulin-5's protein inverse correlated with the degree of malignancy,Ki-67 LI,MVD and the expression of HIF-1αof human gliomas(r=-0.455,-0.779,-0.320;P =0.003,0.000,0.044 ).Then we found that fibulin-5's mRNA always expressed in the normal brain tissue;there were 14 sample could be found in the low grade gliomas tissue;there were only 3 sample could be found in the high grade gliomas tissue.The expression of the fibulin-5's mRNA in the normal brain tissues and the low grade gliomas were higher than its expression in the high grade gliomas(P＞0.05).Conclusion:fibulin-5 could expressed in the normal brain tissue.The expression of fibulin-5 may correlated with the process and the angiogenesis of gliomas.
Part 2 To construct the cell strain(HUVEC-2C) for expressing the fibulin-5 gene through the stable transfection
Objective:To construct an lentiviral vector carrying fibulin-5 gene and then stable transfected to the huaman umbilical vein endothelial cells -2C(HUVEC-2C).Methods:The expression of fibulin-5 in the HUVEC-2C and the U251 was checked by RT-PCR first.Then fibulin-5 was amplified by PCR and subcloned fibulin-5 into the lentiviral vector(pGC-FU),to generate the lentiviral expression vector, (pGC-FU-FIBULIN-5).Recombinant lentiviruses were produced by 293T cells following the co-transfection of pGC-FU-FIBULIN-5,with the packaging plasmids pHelper1.0 and pHelp2.0.So,we got the lentiveruses called KL425-LV.Last,we use the KL425-LV to stable transfect into HUVEC-2C and got the cell strain called Fibulin-5-GFP-LV. Results:There was no expression in the HUVEC-2C and the U251.The cell strain(Fibulin-5-GFP-LV) was expressing the fibulin-5 gene through the check by Western blot and Real-time PCR.Conclusion:The cell strain which was expressing the fibulin-5 gene was successed constructing.
Part 3 Effect on the bionomics of HUVEC-2C by the fibulin-5 gene expressing
Objective:The present study was carried out to investigate the effect on the bionomics of HUVEC-2C by the fibulin-5 gene expressing. Then we could figure out the function of the fibulin-5 during the angiogenesis.Methods:There were three groups in the experiment:CON group(used the normal HUVEC-2C),NC group(used the HUVEC-2C which was transfected the negative vector) and KD group(used the cell strain called Fibulin-5-GFP-LV,which was contructed in the Part 2).So we could exam the change of the ability of the proliferation,adhesion, invasion,apoptosis and vessel-sprouting of the HUVEC-2C during the fibulin-5 gene expressing.Results:By the MTT test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05).In the adhesion's test,the OD value in the KD group was higher than that in the CON group and the NC group(P＜0.05).In the invasion's test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05).By the flow cytometry's test,we found that the cell cycle in the KD group was prolonged(P＜0.05).In the vessel-sprouting abiltity test,we found that the number of the vessel was decreased in the KD group(P＜0.05). Conclusion:The expression of fibulin-5 gene could prolong the period of the cell cycle,inhibit the ability of the proliferation,invasion and the vessel-sprouting of HUVEC-2C.But it could enhance the ability of the adhesion,fibulin-5 gene expressing could inhibit the angiogenesis and make the vessel more stable.
Part 4 Effect on the bionomics of HUVEC-2C and U251 by fibulin-5 gene expressing in the gliomas's microenvironment
Objective:The present study was carried out to investigate the effect on the bionomics of HUVEC-2C or U251 by the fibulin-5 gene expressing in the gliomas's microenvironment.Then we could figure out the function of the fibulin-5 during the process of gliomas.Methods:We first constructed the gliomas's microenvironment by HUVEC-2C and U251 co-cultured.There were three groups in the experiment:CON group(used the normal HUVEC-2C),NC group(used the HUVEC-2C which was transfected the negative vector) and KD group(used the cell strain called Fibulin-5-GFP-LV,which was contructed in the Part 2).So we could exam the change of the ability of the proliferation,adhesion, invasion and vessel-sprouting of the HUVEC-2C during the fibulin-5 gene expressing in the gliomas's microenvironment.We also examed the change of ability of the proliferation and invasion of the U251 by the same way.Results:①Testing the change of the ability of HUVEC-2C's bionomics in the gliomas's microenvironment:By the MTT test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05).In the adhesion's test,the OD value in the KD group was higher than that in the CON group and the NC group (P＜0.05).In the invasion's test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05). In the vessel-sprouting ability test,we found that the number of the vessel was decreased in the KD group(P＜0.05).②Testing the change of the ability of U251's bionomics in the gliomas's microenvironment:By the MTT test,we found that the OD value in the KD group was lower than that in the CON group and the NC group(P＜0.05).In the invasion's test, we found that there were no difference in the KD group,CON group and NC group(P＞0.05).Conclusion:The expression of fibulin-5 gene in the gliomas's microenvironment could inhibit the ability of the proliferation, invasion and the vessel-sprouting of HUVEC-2C.It could enhanced the ability of the adhesion of HUVEC-2C.It could also inhibit the U251 's reproductive activity,fibulin-5 gene expressing could inhibit the angiogenesis and make the vessel more stable in the gliomas's microenvironment.It mightbe make the tumor vessel normalization. Mightbe,it inhibit the gliomas's ability of the proliferation and the invasion directly.
引文
[1]Black PM,Loeffier JS.神经系统肿瘤学(鲍圣德).北京:人民卫生出版社,2008.15-16.
[2]吴在德,吴肇汉.外科学(第6版).北京:人民卫生出版社,2004.281-283.
[3]周良辅.现代神经外科学.上海:复旦大学出版社,2004.375-428.
[4]Faith GD,Sally F,Tames G,et al.Survival rates in patients with primary malignant brain tumors ratified by patient age and tumor histological type:an analysis based on Surveillance,epidemicology,and end results(SEER)data,1973-1991[J].J Neurosurg,1998,88(1):1.
[5]Folkman J,Shing Y.Angiogenesis[J].J Biol Chem,1992,267(16):10931-10934.
[6]Blasberg RG..Molecular imaging and cancer[J].Mol Cancer Ther,2003,2(3):335-343.
[7]Ehrmann RL,Knoth M.Choriocarcinoma.Transfilter stimulation of vasoproliferation in the hamster cheek pouch.Studied by light and electron microscopy[J].J Natl Cancer Inst,1968,41(6):1329-1341.
[8]Greenblatt M,Shubi P.Tumor angiogenesis:transfilter diffusion studies in the hamster by the transparent chamber technique[J].J Natl Cancer Inst,1968,41(1):111-124.
[9]Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186
[10]O'Reilly MS,Holmgren L,Shing Y.Angiostatin:a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma[J].Cell,1994,79(2):315-328.
[11]O'Reilly MS,Boehm T,Shing Y.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth[J].Cell,1997,88(2):277-285.
[12]Plate KH,Risau W.Angiogenesis in malignant gliomas[J].Glia,1995,15:339-347.
[13]Leon SP,Folkerth RD,Black PM.Microvessel density is a pnognostic indicator for patients with astroglial brain tumors[J].Cancer,1996,77(2):362-372.
[14]Brem S.The role of vascular proliferation in the growth of brain tumors[J].Clin Neurosurg,1976,23:440-453.
[15]Folkman J.Endogenous angiogenesis inhibitors[J].APMIS,2004,112:496-507.
[16]Midwood KS and Schwarzbauer JE.Elastic fibers:building bridges between cells and their matrix[J].Curr Biol,2002,12(8):R279-R281.
[17]Lee MJ,Roy NK,Mogford JE,et al.Fibulin-5 promotes wound healing in vivo[J].J Am Coll Surg,2004,199(3):403-410.
[18]Schiemann WP,Blobe GC,Kalume DE,et al.Context-specific effects of fibulin-5(DANCE/EVEC) on cell proliferation,motility,and invasion.Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades[J].J Biol Chem,2002,277(30):27367-27377.
[19]Loeys B,Van-Maldergem L,Mortier G,et al.Homozygosity for a missense mutation in fibulin-5(FBLN5) results in a severe form of cutis laxa[J].Hum Mol Genet,2002,11(18):2113-2118.
[20]Markova D,Zou Y,Ringpfeil F,et al.Genetic heterogeneity of cutis laxa:a heterozygous tandem duplication within the fibulin-5(FBLN5) gene[J].Am J Hum Genet,2003,72(4):998-1004.
[21]Nakamura T,Lozano PR,Ikeda Y,et al.Fibulin-5/DANCE is essential for elastogenesis in vivo[J].Nature,2002,415(6868):171-175.
[22]Yanagisawa H,Davis EC,Starcher BC,et al.Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo[J].Nature,2002,415(6868):168-171.
[23]Schiemann WP,Albig AR.Fibulin-5 function during tumorigenesis[J].Future Oncology,2005,1(1):23-35.
[24]文灿,董世武,余汇祥.人胃癌组织中Fibuliln-5的表达及其临床意义[J].消化外科,2006,5(6):463-465.
[25]Albig AR,Neil JR,Schiemann WP.Fibulins 3 and 5 antagonize tumor angiogenesis in vivo[J].Cancer Res.2006,66(5):2621-2629.
[26]Nakamura T,Ruiz-Lozano P,Lindner V,et al.DANCE,a novel secreted RGD protein expressed in developing,atherosclerotic,and balloon-injured arteries[J].J Biol Chem,1999,274(32):22476-22483.
[27]Remmele W,Stegner HE.Recommendation for uniform definition of an immunoreactive score(IRS) for immunohistochemical estrogen receptor detection(ER-ICA) in breast cancer tissue[J].Pathologe,1987,8(3):138-40.
[28]Ko CD,Kim JS,Ko BG,et al.The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium[J].Clin Exp Metastasis,2003,20(7):593-7.
[29]Ero(?)lu A,Sari A.Expression of c-kit proto-oncogene product in breast cancer tissues[J].Med Oncol,2007,24(2):169-74.
[30] Takeuchi H, Ozawa S, Ando N, et al. Cell-Cycle Regulators and the Ki-67 Labeling Index Can Predict the Response to Chemoradiotherapy and the Survival of Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus[J]. Annals of Surgical Oncology, 2003,10(7):792-800.
[31] Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma[J]. J Natl Cancer, 1992, 84(24): 1875-1887.
[32] Kowal RC,Richardson JA,Miano JM,et al.EVEC, a novel epidermal growth factor-like repeat-containing protein upregulated in embryonic and diseased adult vasculature[J].Circ Res, 1999,84(10): 1166-1176.
[33] Burgdorf WH, Mukai K, Rosai J. Immunohistochemical identification of factor VHI-related antigen in endothelial cells of cutaneous lesions of alleged vascular nature[J].Am J Clin Pathol, 1981,75 (2):167-171
[34] Jensen RL. Growth factor-mediated angiogenesis in the malignanl progression of glial tumors;a review[J].Neurosurg,1998,49(l):189-196.
[35] Holmgren L,O'Reilly MS,Folkman J.Dormancy of micrometastases:balanced proliferation and apoptosis is the presence of angiogenesis suppression[J].Nat Med, 1995,1(2): 149-153.
[36] Tsuruga E,Yajima T,Irie K.Induction of fibulin-5 gene is regulated by tropoelastin gene,and correlated with tropoelastin accumulation in vivo[J].Int J Biochem Cell Biol,2004,36(3):395-400.
[37] Kaur B,Khwaja FW,Severson IA,et al.Hypoxia and the hypoxia-inducible factor pathway in glioma growth and angiogenesis[J].Neuro-oncol,2005,7(2):134-53.
[38] Beasley NJ,Leek R,Alam M,et al.Hypoxia-inducible factors HIF-1 and HIF-2 in head and neck cancenrelationship to tumor biology and treatment outcome in surgically resected patients[J].Cancer Res,2002,62(9):2493-2496.
[39] Fukudar R,Kelly B,Semenza GL.Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostagl and in E2 is mediated by hypoxia-inducible factorl[J].Cancer Res,2003,63(9):2330-2334.
[40] May D,Itin A,Gal O,Kalinski H,et al.Erol-Lalpha plays a key role in a HIF-1 mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia:implication for cancer[J].Oncogene,2005,24(6): 1011-1020.
[41] Gray MJ,Zhang J,Ellis LM,et al.HIF-1 alpha,STAT3, CBP/p300 and Ref-1/APE are components to VEGF in pancreatic and prostate carcinomas[J].Oncogene, 2005,24(19):3110-3120.
[42]Kallio PJ,Okamolo K,O'Brien S,et al.Signal transduction in hypoxic cells:inducible nuclear translocation and recruitment of the CBP/p300coactivator by the hypoxia-inducible factor-lalpha[J].EMBO,1998,17(22):6573-6586.
[43]Ravi R,Mookerjee B,Bhujwalla ZM,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor-la[J].Genes Dev.2000,14(1):34-44.
[44]Albig AR,Schiemann WP.Fibulin-5 antagonizes vascular endothelial growth factor(VEGF) signaling and angiogenic sprouting by endothelial cells[J].DNA Cell Biol,2004,23(6):367-379.
[45]Faria MH,Gon(?)alves BP,do Patrocinio RM,et al.Expression of Ki-67,topoisomerase IIalpha and c-MYC in astrocytic tumors:correlation with the histopathological grade and proliferative status[J].Neuropathology,2006,26(6):519-527.
[46]Johannessen AL,Torp SH.The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas[J].Pathol Oncol Res,2006,12(3):143-147.
[47]Bemy W,Weiser A,Markowska-Woyciechowska A,et al.Analysis of PCNA,Ki67,AgNOR and p53 expression in brain glial tumors[J].Neurol Neurochir Pol,2004,38(6):457-463.
[48]Yue WY,Chen ZP.Does vasculogenic mimicry exist in astrocytoma[J]? J Histochem Cytochem,2005,53(8):997-1002.
[49]Brown J,Reading SJ,Jones S,et al.Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses:a comparison with the human bladder cancer derived epithelial cell line T24/83[J].Lab Invest,2000,80(1):37-45.
[50]Lu X,Humeau L,Slepushkin V,et al.Safe two plasmid production for the first clinical lentivirus vector that achieves>99%transduction in primary cells using a one step protocol[J].J GeneMed,2004,6(9):963-973.
[51]Kappes JC,Wu X,Wakefield JK.Production of trans lentiviral vectorwith predictable safety[J].MethodsMolMed,2003,76(13):449-465.
[52]郑德华,石炳毅,蔡明.慢病毒介导大鼠肾脏基因转染的实验研究[J].山东医药,2004,44(14):325.
[53]Bartosch B,Cosset FL.Strategies for retargeted gene delivery using vectors derived from lentiviruses[J].Curr Gene Ther,2004,4(4):427-443.
[54]Zhang G,Gurtu V,Kain SR.An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells[J].Biochem Biophys Res Commun,1996,227(3):707-711.
[55]Zhang M,Bai CX,Zhang X,et al.Downregulation enhanced green fluorescence protein gene expression by RNA interference in mammalian cells[J].RNA Biol,2004,1(1):74-77.
[56]雷志敏.肿瘤血管形成方式及其分子机制[J].国际口腔医学杂志,2006,33(11):466-468.
[57]Montesano R,Vassalli JD,Baird A,et al.Basic fibroblast growth factor induces angiogenesis in vitro[J].Proc Natl Acad Sci USA,1986,83(19):7297-7301.
[58]Schiemann WP,Blobe GC,Kalume DE,et al.Context-specific effects of fibulin-5(DANCE/EVEC) on cell proliferation,motility,and invasion:Fibulin-5 is induced by TGF-beta and affects protein kinase cascades[J].J Biol Chem,2002,277(30):27367-27377.
[59]Kieran MW.Anti-angiogenic chemotherapy in central nervous system tumors[J].Cancer Treat Res,2004,117:337-349.
[60]Ribatti D,Nico B,Vacca A,et al.Endothelial cell heterogeneity and organ specificity[J].J Hematother Stem Cell Res,2002,11(1):81-90.
[61]Aird WC.Endothelial cell heterogeneity[J].Crit CareMed,2003,31(4 Supp 1):S221-S230.
[62]Alessandri G,Chirivi RG,Castellani P,et al.lsolation and characterization of human tumor-derived capillary endothelial cells:role of oncofetal fibronectin[J].Lab Invest,1998,78(1):127-128.
[63]Giordano F,Mitola S.Characterization of endothelial cells isolated by human meningiomas[J].J Neurosurg Sci,2000,44(4):177-185.
[64]卞修武.血管生成,治疗性血管生成和抗血管生成[J].第三军医大学学报,2001,23(3):249-250.
[65]Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors[J].NatMed,2003,9:669-676.
[66]艾文兵,夏俊,熊志云.整合素AvB3抗体对C6胶质瘤细胞增殖和侵袭力的影响[J].陕西医学杂志,2008,37(1):82-85.
[67]Kabbinavar FF,Schulz J,Mccleod M,et al.Bevacizumab(a monoclonal antibody to vascular endothelial growth factor)to prolong progression-free survival in first-line colorectal cancer(CRC) in subjects who are not suitable candidates for first-line CPT-11[J].J Clin Oncol,2004,22(14Suppl):3516.
[68] Weichselbaum RR.How does antiangiogenic therapy affect brain tumor response to radiation[J]? Nat Clin Pract Oncol,2005,2(5):232-233.
[69] Tong RT,Boucher Y,Kozin SV,et al.Vascular normalization by vascular endothelial growth factor recptor-2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors[J].Cancer Res,2004,64(11):3731-3736.
[70] Dings R P, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization[J].Clin Cancer Res,2007,13(11):3395-3402.
[71] Fukumura D,Jain RK.Tumor microvasculature and microenvironmentrtargets for anti-angiogenesis and normalization[J]. Micro vase Res,2007,74(2-3):72-84.
[1]吴在德,吴肇汉.外科学(第6版).北京:人民卫生出版社,2004.281-283.
[2]Faith GD,Sally F,Tames G,et al.Survival rates in patients with primary malignant brain tumors ratified by patient age and tumor histological type:an analysis based on Surveillance,epidemicology,and end results(SEER)data,1973-1991[J].J Neurosurg,1998,88(1):1.
[3]周良辅.现代神经外科学.上海:复旦大学出版社,2004.375-428.
[4]Plate KH,Risau W.Angiogenesis in malignant gliomas[J].Glia,1995,15:339-347.
[5]Folkman J.Tumor angiogenesis:therapeutic implications.N Engl J Med,1971,285(21):1182-1186
[6]Goldman E.The growth of malignant disease in men with special reference to the vascular system.Proc R Soc Med,1907,1:1.
[7]Ide AG,Baker N,Warren S.Vascularization of the Brown-Peance rabbit epithelium transplant as seen in the transplant ear chamber[J].AJR Am J Roentgenol,1939,42:89-99.
[8]Greenblatt M,Shubik P.Tumor angiogenesis:trans-filter diffusion studies in the hamster by the transparent chamber technique[J].J Natl Cancer Inst,1968,41(1):111-124.
[9]Folkman J,Long D,Becker F.Growth and metastasis of tumor in organ culture[J].Cancer,1963,16(4):453-467.
[10]Folkman J.What is the evidence that tumors are angiogenesis dependent?[J].J Natl Cancer Inst,1990,82(1):4-6
[11]Osthoff K,Risav W,Vollmer E,et,al.In situ detection of bFGF by highly specific antibodies[J].Am J Pathol,1990,137(1):85-92.
[12]Vladavsky I,Fuks Z,Michaeli R,et,al.Extracellular matrix-resident bFGF:implication for the control of angiogenesis[J].J Cell Biochem,1991,45(2):167-176.
[13]Leibovich S,Polverini P,Shepard H,et,al.Macrophage-induced angiogenesis is mediated by TNF-α[J].Nature,1987,329(6140):630-633.
[14]Polverini P,Leibovich S.Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor associated macrophages[J].Lab Invest,1984,51(6):635-642.
[15]Auguste P,Lemiere S,Larrieu-Lahargue F,et,al.Crit Rev Oncol Hematol,2005,54(1):53-61.
[16]Black PM,Loeffler JS.神经系统肿瘤学(鲍圣德).北京:人民卫生出版社,2008.570.
[17]Auguste P,G(u|¨)rsel DB,Lemi(?)re S,et,al.Inhibition of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Activity in Glioma Cells Impedes Tumor Growth by Both Angiogenesis-dependent and -independent Mechanisms[J].Cancer Res,2001,61(4):1717-1726.
[18]Fukumura D,Jain RK.Tumor microvasculature and microenvironment:targets for anti-angiogenesis and normalization[J].Microvasc Res,2007,74(2-3):72-84.
[19]Ribatti D,Nico B,Vacca A,et,al.Chorioallantoic membrane capillary bed:a useful target for studying angiogenesis and anti-angiogenesis in vivo[J].Anat Rec,2001,264(4):317-324.
[20]林健,王伟明,徐如祥.C6大鼠胶质瘤模型及其在脑胶质瘤治疗研究中应用的缺陷[J].中华神经医学杂志,2003,2(2):154-156.
[21]Kieran MW.Anti-angiogenic chemotherapy in central nervous system tumors [J].Cancer Treat Res,2004,117:337-349.
[22]Tischer E,Michell R,Hartman T,et,al.The human gene for vascular endothelial growth factor[J].J Biol Chem,1991,266(18):11945-11947.
[23]Conn G,Bayne ML,Soderman DD,et,al.Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor[J].Proc Natl Acad Sci USA,1990,87(7):2628-2632.
[24]Ferrara N,Houck K,Jakeman L,et,al.Molecular and biological properties of the vascular endothelial growth factor family of proteins[J].Endocrinol Rev,1992,13(1):18-32.
[25]Tuettenberg J,Friedel C,Vajkoczy P.Angiogenesis in malignant glioma-a target for antitumor therapy?[J].Crit Rev Oncol Hematol,2006,59(3):181-193.
[26]Shweiki D,Itin A,Soffer D,et,al.Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis[J].Nature,1992,359(10):843-845.
[27]Xu ZP,Tsuji T,Riordan JF,et al.The nuclear function of angiogenin in endothelial cells is related to rRNA production[J].Biochem Biophys Res Commun,2002,294(2):287-292.
[28] Albig AR , Neil JR, Schiemann WP. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo[J]. Cancer Res. 2006,66(5):2621-2629.
[29] Folkman J. Endogenous angiogenesis inhibitors[J]. APMIS,2004,112:496-507.
[30] Joe YA,Hong YK,Chung DS,et,al.Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3[J].Int J Cancer, 1999,82(5):694-699.
[31] Vredenburgh JJ,Desjardins A,Herndon JE 2 nd,et al.Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma[J].Clin Cancer Res,2007,13(2):1253-1259.
[32] Erber R,Thumber A,Katsen AD,et al.Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms[J].FASEB J,2004,18:338-340.
[33] Kunkel P,Ulbricht U,Bohlen P,et al.Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2[J].Cancer Res,2001,61(9):6624-6628.
[34] Kabbinavar FF,Schulz J,Mccleod M,et al.Bevacizumab(a monoclonal antibody to vascular endothelial growth factor)to prolong progression-free survival in first-line colorectal cancer(CRC) in subjects who are not suitable candidates for first-line CPT-11[J].J Clin Oncol,2004,22(14Suppl):3516.
[35] Weichselbaum RR.How does antiangiogenic therapy affect brain tumor response to radiation[J]? Nat Clin Pract Oncol,2005,2(5):232-233.
[36] Tong RT,Boucher Y,Kozin SV,et al.Vascular normalization by vascular endothelial growth factor recptor-2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors[J].Cancer Res,2004,64(11):3731-3736.
[37] Dings R P, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization[J].Clin Cancer Res,2007,13(11):3395-3402.
[38] Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J].Science,2005,307(5706):58-62.
[2]吴在德,吴肇汉.外科学(第6版).北京:人民卫生出版社,2004.281-283.
[3]周良辅.现代神经外科学.上海:复旦大学出版社,2004.375-428.
[4]Faith GD,Sally F,Tames G,et al.Survival rates in patients with primary malignant brain tumors ratified by patient age and tumor histological type:an analysis based on Surveillance,epidemicology,and end results(SEER)data,1973-1991[J].J Neurosurg,1998,88(1):1.
[5]Folkman J,Shing Y.Angiogenesis[J].J Biol Chem,1992,267(16):10931-10934.
[6]Blasberg RG..Molecular imaging and cancer[J].Mol Cancer Ther,2003,2(3):335-343.
[7]Ehrmann RL,Knoth M.Choriocarcinoma.Transfilter stimulation of vasoproliferation in the hamster cheek pouch.Studied by light and electron microscopy[J].J Natl Cancer Inst,1968,41(6):1329-1341.
[8]Greenblatt M,Shubi P.Tumor angiogenesis:transfilter diffusion studies in the hamster by the transparent chamber technique[J].J Natl Cancer Inst,1968,41(1):111-124.
[9]Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186
[10]O'Reilly MS,Holmgren L,Shing Y.Angiostatin:a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma[J].Cell,1994,79(2):315-328.
[11]O'Reilly MS,Boehm T,Shing Y.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth[J].Cell,1997,88(2):277-285.
[12]Plate KH,Risau W.Angiogenesis in malignant gliomas[J].Glia,1995,15:339-347.
[13]Leon SP,Folkerth RD,Black PM.Microvessel density is a pnognostic indicator for patients with astroglial brain tumors[J].Cancer,1996,77(2):362-372.
[14]Brem S.The role of vascular proliferation in the growth of brain tumors[J].Clin Neurosurg,1976,23:440-453.
[15]Folkman J.Endogenous angiogenesis inhibitors[J].APMIS,2004,112:496-507.
[16]Midwood KS and Schwarzbauer JE.Elastic fibers:building bridges between cells and their matrix[J].Curr Biol,2002,12(8):R279-R281.
[17]Lee MJ,Roy NK,Mogford JE,et al.Fibulin-5 promotes wound healing in vivo[J].J Am Coll Surg,2004,199(3):403-410.
[18]Schiemann WP,Blobe GC,Kalume DE,et al.Context-specific effects of fibulin-5(DANCE/EVEC) on cell proliferation,motility,and invasion.Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades[J].J Biol Chem,2002,277(30):27367-27377.
[19]Loeys B,Van-Maldergem L,Mortier G,et al.Homozygosity for a missense mutation in fibulin-5(FBLN5) results in a severe form of cutis laxa[J].Hum Mol Genet,2002,11(18):2113-2118.
[20]Markova D,Zou Y,Ringpfeil F,et al.Genetic heterogeneity of cutis laxa:a heterozygous tandem duplication within the fibulin-5(FBLN5) gene[J].Am J Hum Genet,2003,72(4):998-1004.
[21]Nakamura T,Lozano PR,Ikeda Y,et al.Fibulin-5/DANCE is essential for elastogenesis in vivo[J].Nature,2002,415(6868):171-175.
[22]Yanagisawa H,Davis EC,Starcher BC,et al.Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo[J].Nature,2002,415(6868):168-171.
[23]Schiemann WP,Albig AR.Fibulin-5 function during tumorigenesis[J].Future Oncology,2005,1(1):23-35.
[24]文灿,董世武,余汇祥.人胃癌组织中Fibuliln-5的表达及其临床意义[J].消化外科,2006,5(6):463-465.
[25]Albig AR,Neil JR,Schiemann WP.Fibulins 3 and 5 antagonize tumor angiogenesis in vivo[J].Cancer Res.2006,66(5):2621-2629.
[26]Nakamura T,Ruiz-Lozano P,Lindner V,et al.DANCE,a novel secreted RGD protein expressed in developing,atherosclerotic,and balloon-injured arteries[J].J Biol Chem,1999,274(32):22476-22483.
[27]Remmele W,Stegner HE.Recommendation for uniform definition of an immunoreactive score(IRS) for immunohistochemical estrogen receptor detection(ER-ICA) in breast cancer tissue[J].Pathologe,1987,8(3):138-40.
[28]Ko CD,Kim JS,Ko BG,et al.The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium[J].Clin Exp Metastasis,2003,20(7):593-7.
[29]Ero(?)lu A,Sari A.Expression of c-kit proto-oncogene product in breast cancer tissues[J].Med Oncol,2007,24(2):169-74.
[30] Takeuchi H, Ozawa S, Ando N, et al. Cell-Cycle Regulators and the Ki-67 Labeling Index Can Predict the Response to Chemoradiotherapy and the Survival of Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus[J]. Annals of Surgical Oncology, 2003,10(7):792-800.
[31] Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma[J]. J Natl Cancer, 1992, 84(24): 1875-1887.
[32] Kowal RC,Richardson JA,Miano JM,et al.EVEC, a novel epidermal growth factor-like repeat-containing protein upregulated in embryonic and diseased adult vasculature[J].Circ Res, 1999,84(10): 1166-1176.
[33] Burgdorf WH, Mukai K, Rosai J. Immunohistochemical identification of factor VHI-related antigen in endothelial cells of cutaneous lesions of alleged vascular nature[J].Am J Clin Pathol, 1981,75 (2):167-171
[34] Jensen RL. Growth factor-mediated angiogenesis in the malignanl progression of glial tumors;a review[J].Neurosurg,1998,49(l):189-196.
[35] Holmgren L,O'Reilly MS,Folkman J.Dormancy of micrometastases:balanced proliferation and apoptosis is the presence of angiogenesis suppression[J].Nat Med, 1995,1(2): 149-153.
[36] Tsuruga E,Yajima T,Irie K.Induction of fibulin-5 gene is regulated by tropoelastin gene,and correlated with tropoelastin accumulation in vivo[J].Int J Biochem Cell Biol,2004,36(3):395-400.
[37] Kaur B,Khwaja FW,Severson IA,et al.Hypoxia and the hypoxia-inducible factor pathway in glioma growth and angiogenesis[J].Neuro-oncol,2005,7(2):134-53.
[38] Beasley NJ,Leek R,Alam M,et al.Hypoxia-inducible factors HIF-1 and HIF-2 in head and neck cancenrelationship to tumor biology and treatment outcome in surgically resected patients[J].Cancer Res,2002,62(9):2493-2496.
[39] Fukudar R,Kelly B,Semenza GL.Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostagl and in E2 is mediated by hypoxia-inducible factorl[J].Cancer Res,2003,63(9):2330-2334.
[40] May D,Itin A,Gal O,Kalinski H,et al.Erol-Lalpha plays a key role in a HIF-1 mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia:implication for cancer[J].Oncogene,2005,24(6): 1011-1020.
[41] Gray MJ,Zhang J,Ellis LM,et al.HIF-1 alpha,STAT3, CBP/p300 and Ref-1/APE are components to VEGF in pancreatic and prostate carcinomas[J].Oncogene, 2005,24(19):3110-3120.
[42]Kallio PJ,Okamolo K,O'Brien S,et al.Signal transduction in hypoxic cells:inducible nuclear translocation and recruitment of the CBP/p300coactivator by the hypoxia-inducible factor-lalpha[J].EMBO,1998,17(22):6573-6586.
[43]Ravi R,Mookerjee B,Bhujwalla ZM,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor-la[J].Genes Dev.2000,14(1):34-44.
[44]Albig AR,Schiemann WP.Fibulin-5 antagonizes vascular endothelial growth factor(VEGF) signaling and angiogenic sprouting by endothelial cells[J].DNA Cell Biol,2004,23(6):367-379.
[45]Faria MH,Gon(?)alves BP,do Patrocinio RM,et al.Expression of Ki-67,topoisomerase IIalpha and c-MYC in astrocytic tumors:correlation with the histopathological grade and proliferative status[J].Neuropathology,2006,26(6):519-527.
[46]Johannessen AL,Torp SH.The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas[J].Pathol Oncol Res,2006,12(3):143-147.
[47]Bemy W,Weiser A,Markowska-Woyciechowska A,et al.Analysis of PCNA,Ki67,AgNOR and p53 expression in brain glial tumors[J].Neurol Neurochir Pol,2004,38(6):457-463.
[48]Yue WY,Chen ZP.Does vasculogenic mimicry exist in astrocytoma[J]? J Histochem Cytochem,2005,53(8):997-1002.
[49]Brown J,Reading SJ,Jones S,et al.Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses:a comparison with the human bladder cancer derived epithelial cell line T24/83[J].Lab Invest,2000,80(1):37-45.
[50]Lu X,Humeau L,Slepushkin V,et al.Safe two plasmid production for the first clinical lentivirus vector that achieves>99%transduction in primary cells using a one step protocol[J].J GeneMed,2004,6(9):963-973.
[51]Kappes JC,Wu X,Wakefield JK.Production of trans lentiviral vectorwith predictable safety[J].MethodsMolMed,2003,76(13):449-465.
[52]郑德华,石炳毅,蔡明.慢病毒介导大鼠肾脏基因转染的实验研究[J].山东医药,2004,44(14):325.
[53]Bartosch B,Cosset FL.Strategies for retargeted gene delivery using vectors derived from lentiviruses[J].Curr Gene Ther,2004,4(4):427-443.
[54]Zhang G,Gurtu V,Kain SR.An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells[J].Biochem Biophys Res Commun,1996,227(3):707-711.
[55]Zhang M,Bai CX,Zhang X,et al.Downregulation enhanced green fluorescence protein gene expression by RNA interference in mammalian cells[J].RNA Biol,2004,1(1):74-77.
[56]雷志敏.肿瘤血管形成方式及其分子机制[J].国际口腔医学杂志,2006,33(11):466-468.
[57]Montesano R,Vassalli JD,Baird A,et al.Basic fibroblast growth factor induces angiogenesis in vitro[J].Proc Natl Acad Sci USA,1986,83(19):7297-7301.
[58]Schiemann WP,Blobe GC,Kalume DE,et al.Context-specific effects of fibulin-5(DANCE/EVEC) on cell proliferation,motility,and invasion:Fibulin-5 is induced by TGF-beta and affects protein kinase cascades[J].J Biol Chem,2002,277(30):27367-27377.
[59]Kieran MW.Anti-angiogenic chemotherapy in central nervous system tumors[J].Cancer Treat Res,2004,117:337-349.
[60]Ribatti D,Nico B,Vacca A,et al.Endothelial cell heterogeneity and organ specificity[J].J Hematother Stem Cell Res,2002,11(1):81-90.
[61]Aird WC.Endothelial cell heterogeneity[J].Crit CareMed,2003,31(4 Supp 1):S221-S230.
[62]Alessandri G,Chirivi RG,Castellani P,et al.lsolation and characterization of human tumor-derived capillary endothelial cells:role of oncofetal fibronectin[J].Lab Invest,1998,78(1):127-128.
[63]Giordano F,Mitola S.Characterization of endothelial cells isolated by human meningiomas[J].J Neurosurg Sci,2000,44(4):177-185.
[64]卞修武.血管生成,治疗性血管生成和抗血管生成[J].第三军医大学学报,2001,23(3):249-250.
[65]Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors[J].NatMed,2003,9:669-676.
[66]艾文兵,夏俊,熊志云.整合素AvB3抗体对C6胶质瘤细胞增殖和侵袭力的影响[J].陕西医学杂志,2008,37(1):82-85.
[67]Kabbinavar FF,Schulz J,Mccleod M,et al.Bevacizumab(a monoclonal antibody to vascular endothelial growth factor)to prolong progression-free survival in first-line colorectal cancer(CRC) in subjects who are not suitable candidates for first-line CPT-11[J].J Clin Oncol,2004,22(14Suppl):3516.
[68] Weichselbaum RR.How does antiangiogenic therapy affect brain tumor response to radiation[J]? Nat Clin Pract Oncol,2005,2(5):232-233.
[69] Tong RT,Boucher Y,Kozin SV,et al.Vascular normalization by vascular endothelial growth factor recptor-2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors[J].Cancer Res,2004,64(11):3731-3736.
[70] Dings R P, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization[J].Clin Cancer Res,2007,13(11):3395-3402.
[71] Fukumura D,Jain RK.Tumor microvasculature and microenvironmentrtargets for anti-angiogenesis and normalization[J]. Micro vase Res,2007,74(2-3):72-84.
[1]吴在德,吴肇汉.外科学(第6版).北京:人民卫生出版社,2004.281-283.
[2]Faith GD,Sally F,Tames G,et al.Survival rates in patients with primary malignant brain tumors ratified by patient age and tumor histological type:an analysis based on Surveillance,epidemicology,and end results(SEER)data,1973-1991[J].J Neurosurg,1998,88(1):1.
[3]周良辅.现代神经外科学.上海:复旦大学出版社,2004.375-428.
[4]Plate KH,Risau W.Angiogenesis in malignant gliomas[J].Glia,1995,15:339-347.
[5]Folkman J.Tumor angiogenesis:therapeutic implications.N Engl J Med,1971,285(21):1182-1186
[6]Goldman E.The growth of malignant disease in men with special reference to the vascular system.Proc R Soc Med,1907,1:1.
[7]Ide AG,Baker N,Warren S.Vascularization of the Brown-Peance rabbit epithelium transplant as seen in the transplant ear chamber[J].AJR Am J Roentgenol,1939,42:89-99.
[8]Greenblatt M,Shubik P.Tumor angiogenesis:trans-filter diffusion studies in the hamster by the transparent chamber technique[J].J Natl Cancer Inst,1968,41(1):111-124.
[9]Folkman J,Long D,Becker F.Growth and metastasis of tumor in organ culture[J].Cancer,1963,16(4):453-467.
[10]Folkman J.What is the evidence that tumors are angiogenesis dependent?[J].J Natl Cancer Inst,1990,82(1):4-6
[11]Osthoff K,Risav W,Vollmer E,et,al.In situ detection of bFGF by highly specific antibodies[J].Am J Pathol,1990,137(1):85-92.
[12]Vladavsky I,Fuks Z,Michaeli R,et,al.Extracellular matrix-resident bFGF:implication for the control of angiogenesis[J].J Cell Biochem,1991,45(2):167-176.
[13]Leibovich S,Polverini P,Shepard H,et,al.Macrophage-induced angiogenesis is mediated by TNF-α[J].Nature,1987,329(6140):630-633.
[14]Polverini P,Leibovich S.Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor associated macrophages[J].Lab Invest,1984,51(6):635-642.
[15]Auguste P,Lemiere S,Larrieu-Lahargue F,et,al.Crit Rev Oncol Hematol,2005,54(1):53-61.
[16]Black PM,Loeffler JS.神经系统肿瘤学(鲍圣德).北京:人民卫生出版社,2008.570.
[17]Auguste P,G(u|¨)rsel DB,Lemi(?)re S,et,al.Inhibition of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Activity in Glioma Cells Impedes Tumor Growth by Both Angiogenesis-dependent and -independent Mechanisms[J].Cancer Res,2001,61(4):1717-1726.
[18]Fukumura D,Jain RK.Tumor microvasculature and microenvironment:targets for anti-angiogenesis and normalization[J].Microvasc Res,2007,74(2-3):72-84.
[19]Ribatti D,Nico B,Vacca A,et,al.Chorioallantoic membrane capillary bed:a useful target for studying angiogenesis and anti-angiogenesis in vivo[J].Anat Rec,2001,264(4):317-324.
[20]林健,王伟明,徐如祥.C6大鼠胶质瘤模型及其在脑胶质瘤治疗研究中应用的缺陷[J].中华神经医学杂志,2003,2(2):154-156.
[21]Kieran MW.Anti-angiogenic chemotherapy in central nervous system tumors [J].Cancer Treat Res,2004,117:337-349.
[22]Tischer E,Michell R,Hartman T,et,al.The human gene for vascular endothelial growth factor[J].J Biol Chem,1991,266(18):11945-11947.
[23]Conn G,Bayne ML,Soderman DD,et,al.Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor[J].Proc Natl Acad Sci USA,1990,87(7):2628-2632.
[24]Ferrara N,Houck K,Jakeman L,et,al.Molecular and biological properties of the vascular endothelial growth factor family of proteins[J].Endocrinol Rev,1992,13(1):18-32.
[25]Tuettenberg J,Friedel C,Vajkoczy P.Angiogenesis in malignant glioma-a target for antitumor therapy?[J].Crit Rev Oncol Hematol,2006,59(3):181-193.
[26]Shweiki D,Itin A,Soffer D,et,al.Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis[J].Nature,1992,359(10):843-845.
[27]Xu ZP,Tsuji T,Riordan JF,et al.The nuclear function of angiogenin in endothelial cells is related to rRNA production[J].Biochem Biophys Res Commun,2002,294(2):287-292.
[28] Albig AR , Neil JR, Schiemann WP. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo[J]. Cancer Res. 2006,66(5):2621-2629.
[29] Folkman J. Endogenous angiogenesis inhibitors[J]. APMIS,2004,112:496-507.
[30] Joe YA,Hong YK,Chung DS,et,al.Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3[J].Int J Cancer, 1999,82(5):694-699.
[31] Vredenburgh JJ,Desjardins A,Herndon JE 2 nd,et al.Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma[J].Clin Cancer Res,2007,13(2):1253-1259.
[32] Erber R,Thumber A,Katsen AD,et al.Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms[J].FASEB J,2004,18:338-340.
[33] Kunkel P,Ulbricht U,Bohlen P,et al.Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2[J].Cancer Res,2001,61(9):6624-6628.
[34] Kabbinavar FF,Schulz J,Mccleod M,et al.Bevacizumab(a monoclonal antibody to vascular endothelial growth factor)to prolong progression-free survival in first-line colorectal cancer(CRC) in subjects who are not suitable candidates for first-line CPT-11[J].J Clin Oncol,2004,22(14Suppl):3516.
[35] Weichselbaum RR.How does antiangiogenic therapy affect brain tumor response to radiation[J]? Nat Clin Pract Oncol,2005,2(5):232-233.
[36] Tong RT,Boucher Y,Kozin SV,et al.Vascular normalization by vascular endothelial growth factor recptor-2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors[J].Cancer Res,2004,64(11):3731-3736.
[37] Dings R P, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization[J].Clin Cancer Res,2007,13(11):3395-3402.
[38] Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J].Science,2005,307(5706):58-62.